SYS-CON MEDIA Authors: Lori MacVittie, Gilad Parann-Nissany, Unitiv Blog, Bob Gourley, Kevin Benedict

News Feed Item

Conference Schedules, Stock Price Movements, Executive Transitions, and Revenue Outlook - Research Report on Incyte, ViroPharma, Cooper, Varian and PDL BioPharma

NEW YORK, December 30, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Incyte Corporation (NASDAQ: INCY), ViroPharma Inc. (NASDAQ: VPHM), The Cooper Companies Inc. (NYSE: COO), Varian Medical Systems Inc. (NYSE: VAR) and PDL BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Incyte Corporation Research Report

On December 18, 2013, Incyte Corp. (Incyte) announced that it is scheduled to present at the 32nd Annual J. P. Morgan Healthcare Conference on January 13, 2014 at 8:30 a.m. PST/11:30 a.m. EST in San Francisco. The Company added that the presentation will be webcast live and can be accessed at its website under "Investor Relations, Events and Webcasts". The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


ViroPharma Inc. Research Report

On December 24, 2013, ViroPharma Inc. (ViroPharma) stock rose to end the day at $49.86, compared to the previous day's closing price of $49.83. The Company's stock went up by 0.18% over the past three trading days, compared to the Nasdaq Composite, which gained 2.40% during the same trading period. The Full Research Report on ViroPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


The Cooper Companies Inc. Research Report

On December 18, 2013, The Cooper Companies Inc. (Cooper) reported that it will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2014 at 2:30 p.m. PT/5:30 p.m. ET. Cooper stated that President and CEO Robert S. Weiss, and Vice President and Chief Strategy Officer, Albert G. White, III, will speak on behalf of the Company. The Company added that live audio webcast of the presentation can be accessed via the Investor Relations section of its website. The Full Research Report on The Cooper Companies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Varian Medical Systems Inc. Research Report

On December 16, 2013, Varian Medical Systems Inc. (Varian) announced the retirement of Robert H. Kluge as the Company's Senior Vice President and President, Imaging Components Businesses, effective February 7, 2014. Varian informed that Sunny Sanyal, CEO of T-System, has been named by the Company CEO Dow R. Wilson and appointed by the Board of Directors to assume the position of Mr. Kluge, effective February 3, 2014. Wilson commented, "We are indebted to Bob for his strategic vision, intelligent management, and consistent execution that have propelled Varian to a leadership position in the global imaging industry. He has set the stage for continued success and growth in our components businesses." He further added, "Sunny Sanyal is an experienced leader who will work with our seasoned imaging components management team to expand and capitalize on the growth potential for these businesses. We look forward under Sunny's leadership to building these businesses into a billion dollar platform for Varian." The Full Research Report on Varian Medical Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


PDL BioPharma, Inc. Research Report

On December 10, 2013, PDL BioPharma, Inc. (PDL) announced its revenue guidance for Q4 2013. The Company stated that it anticipates approximately $109 million in revenues, as compared with actual revenue of $86 million for the Q4 2012, representing a 26.7% YoY increase. The Company stated that the forecasted revenue growth is driven by increased Q3 2013 sales for Avastin®, Herceptin®, Lucentis®, Xolair®, Kadcyla®, Perjeta®, and Actemra® for which PDL receives royalties in the Q4 2013, along with the addition of the royalty payments from the Company's purchase of Depomed's diabetes-related royalties. According to PDL, revenue guidance for Q4 2013 is net of an estimated payment due under the Company's February 2011 settlement agreement with Novartis AG. The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.